Prostate-specific membrane antigen (PSMA) immunoexpression in the neovasculature of colorectal carcinoma in,Egyptian patients

被引:14
|
作者
Abdel-Hadi, Mona [1 ]
Ismail, Yasser [1 ]
Younis, Layla [1 ]
机构
[1] Univ Alexandria, Fac Med, Dept Pathol, Alexandria, Egypt
关键词
lmmunoexpression; PSMA; Colorectal carcinoma (CRC); Neovasculature; TUMOR-ASSOCIATED NEOVASCULATURE; MONOCLONAL-ANTIBODIES; MICROVESSEL DENSITY; PROGNOSTIC-FACTORS; CANCER; EXPRESSION; ANGIOGENESIS; MARKER; AGE; ENDOTHELIUM;
D O I
10.1016/j.prp.2014.05.015
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
In Egypt colorectal carcinoma (CRC) is the most common type of malignancy of the digestive system. Selectively inhibiting neoangiogenesis by targeting tumor-associated blood vessels is an important therapeutic strategy. Prostate specific membrane antigen (PSMA) is expressed in the tumor-associated neovasculature of most solid cancers making it an interesting therapeutic target. We thought to study the expression of PSMA in a series of CRCs in order to test for its possible use as a target for antiangiogenic cancer therapy in Egyptian patients. One hundred CRC cases were retrieved. Representative sections from each tumor were subjected to immunohistochemistry using PSMA antibodies and CD31 antibodies as reference marker. Accordingly vascular endothelial cell immunoreactivity was semiquantitatively scored. PSMA immunostaining was positive in the neovasculature of 75% of tumors. A statistically significant relation was found between PSMA immunostaining and distant metastasis as well as vascular invasion. The present findings strengthen the evidence on the potential usefulness of PSMA as a therapeutic vascular target. This study is the first to demonstrate a positive relation between PSMA expression in CRC and distant metastasis as well vascular invasion, suggesting that PSMA may play a significant role in vascular invasion and subsequent metastasis. (C) 2014 Elsevier GmbH. All rights reserved.
引用
收藏
页码:759 / 763
页数:5
相关论文
共 50 条
  • [41] Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells
    Kranzbuhler, Benedikt
    Salemi, Souzan
    Umbricht, Christoph A.
    Mueller, Cristina
    Burger, Irene A.
    Sulser, Tullio
    Eberli, Daniel
    PROSTATE, 2018, 78 (10): : 758 - 765
  • [42] Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells
    Lapidus, RG
    Tiffany, CW
    Isaacs, JT
    Slusher, BS
    PROSTATE, 2000, 45 (04): : 350 - 354
  • [43] Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging
    Topoozian, Mark
    Calais, Jeremie
    Felker, Ely
    Sisk, Anthony
    Gonzalez, Samantha
    Lee, Sean J.
    Marks, Leonard S.
    UROLOGY CASE REPORTS, 2023, 50
  • [44] Prostate-Specific Membrane Antigen (PSMA) targeted prodrug "smartbombs" as therapy for prostate cancer
    Mhaka, Annastasiah
    Singh, Pratap
    Rosen, Marc
    Dionne, Craig A.
    Christensen, Soeren B.
    Isaacs, John T.
    Denmeade, Samuel R.
    CANCER RESEARCH, 2006, 66 (08)
  • [45] Prostate-Specific Membrane Antigen (PSMA) Expression in Benign and Malignant Tunisian Prostate Tumours
    Ben Jemaa, A.
    Sallami, S.
    Bouraoui, Y.
    Horchani, A.
    Ben Lamine, H.
    Ouertani, L.
    Oueslati, R.
    TUMOR BIOLOGY, 2008, 29 : 57 - 57
  • [46] Preclinical evaluation of prostate-specific membrane antigen (PSMA)-based radiotheranostics for metastatic renal cell carcinoma
    Thotakura, Anand
    Singh, Rajan
    Alati, Suresh
    Ala, Lisok
    Jiang, Zirui
    Singla, Nirmish
    Ged, Yasser
    Minn, Il
    Merino, Vanessa
    Horti, Andrew
    Slones, Lilja
    Pomper, Martin
    Rowe, Steven
    Ray, Sangeeta
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [47] The era of prostate-specific membrane antigen (PSMA)-based theranostics for hepatocellular carcinoma is upcoming: are we ready for it?
    Filippi, Luca
    Braat, Arthur J.
    Schillaci, Orazio
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (12) : 3977 - 3978
  • [48] The era of prostate-specific membrane antigen (PSMA)–based theranostics for hepatocellular carcinoma is upcoming: are we ready for it?
    Luca Filippi
    Arthur J. Braat
    Orazio Schillaci
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3977 - 3978
  • [49] Induction of antibodies against prostate-specific membrane antigen (PSMA) by vaccination with a PSMA DNA vector
    Kuratsukuri, K
    Wang, CY
    Sone, T
    Nishisaka, N
    Jones, RF
    Haas, GP
    EUROPEAN UROLOGY, 2002, 42 (01) : 67 - 73